Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Revenue projections:

Revenue projections for SYNGENE
Revenue projections for SYNGENE

With SYNGENE's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 0.00000
forwardPE 41.54316
debtToEquity 12.28300
earningsGrowth -0.87400
revenueGrowth -0.02800
grossMargins 0.68297
operatingMargins 0.12943
trailingEps 8.76000
forwardEps 13.09000

SYNGENE's low Debt-to-Equity ratio reflects limited reliance on debt, signaling the company is not over-leveraged. This lower financial risk suggests that SYNGENE has a strong capital structure, which can help sustain long-term stability and attract cautious investors.
With both earnings and revenue growth in low territory, SYNGENE is likely to see shrinking profits. This signals a possible downturn in the company's financial health and may raise concerns about its future profitability.
SYNGENE's negative gross and operating margins suggest that the company is struggling to cover its production and operating costs, leading to losses. This reflects a weakened financial state and potential difficulties in sustaining profitability.
SYNGENE's forward EPS exceeds its trailing EPS, indicating that the company is projected to be more profitable in the current financial year compared to the previous one. This suggests positive growth and improved earnings, signaling an optimistic outlook for SYNGENE's financial performance.

Price projections:

Price projections for SYNGENE
Price projections for SYNGENE

SYNGENE's price projections have gradually decreased, indicating a more conservative outlook from analysts. The repeated downward revisions suggest waning confidence in the company's ability to achieve its previous targets.

Insider Transactions:

Insider Transactions for SYNGENE
Insider Transactions for SYNGENE


Syngene International Limited had 4 sell transactions, while the market price was at 875.0624847412109 per share.There were no sell transactions during the given timeframe.The recent trend of increased buying at SYNGENE's current price levels may indicate a favorable market sentiment. This could point to a positive outlook for the stock, as investors show growing confidence through higher buy activity.

Recommendation changes over time:

Recommendations trend for SYNGENE
Recommendations trend for SYNGENE


The recent buy bias from analysts suggests SYNGENE is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, SYNGENE appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.